Evidence map›Paper›PMID 25822732›Full record

ArticleMolecular imaging and biology2015

MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [(18)F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation.

Nathalie Matusiak, Aren van Waarde, Dennie Rozeveld, Antoon J M van Oosterhout, Irene H Heijink, Riccardo Castelli, Herman S Overkleeft, Rainer Bischoff, Rudi A J O Dierckx, Philip H Elsinga

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nathalie MatusiakDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ, Groningen, The Netherlands. nathaliematusiak@yahoo.fr.
Aren van WaardeDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ, Groningen, The Netherlands.
Dennie RozeveldLaboratory of Allergy and Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Antoon J M van OosterhoutLaboratory of Allergy and Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Irene H HeijinkLaboratory of Allergy and Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Riccardo CastelliLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Herman S OverkleeftLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Rainer BischoffDepartment of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ, Groningen, The Netherlands.
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ, Groningen, The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NLLeiden University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix metalloproteinases (MMPs) are the main proteolytic enzymes involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). A radiolabeled MMP inhibitor, [(18)F]FB-ML5, was prepared, and its in vivo kinetics were tested in a mouse model of pulmonary inflammation. BALB/c mice were exposed for 4 days to cigarette smoke (CS) or air. On the fifth day, a dynamic microPET scan was made with [(18)F]FB-ML5. Standardized uptake values (PET-SUVmean) were 0.19 ± 0.06 in the lungs of CS-exposed mice (n = 6) compared to 0.11 ± 0.03 (n = 5) in air-exposed controls (p < 0.05), 90 min post-injection MMP-9 levels in bronchoalveolar lavage fluid (BALF) were increased from undetectable level to 4615 ± 1963 pg/ml by CS exposure. Increased MMP expression in a COPD mouse model was shown to lead to increased retention of [(18)F]FB-ML5.

Indexed as

AnimalsDisease Models, AnimalMaleMatrix Metalloproteinase InhibitorsMice, Inbred BALB CNicotianaPneumoniaPositron-Emission TomographyPulmonary Disease, Chronic ObstructiveSmokeMatrix Metalloproteinase InhibitorsSmokeBALFCOPDLung imagingMicroPETMMP/ADAM inhibitor

Identifiers

PMID25822732
OpenAlexW2155353529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.